BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38218283)

  • 1. Discovery of furopyridine-based compounds as novel inhibitors of Janus kinase 2: In silico and in vitro studies.
    Suriya U; Mahalapbutr P; Geronikaki A; Kartsev V; Zubenko A; Divaeva L; Chekrisheva V; Petrou A; Oopkaew L; Somngam P; Choowongkomon K; Rungrotmongkol T
    Int J Biol Macromol; 2024 Mar; 260(Pt 2):129308. PubMed ID: 38218283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Silico and In Vitro Study of Janus Kinases Inhibitors from Naphthoquinones.
    Sanachai K; Mahalapbutr P; Tabtimmai L; Seetaha S; Kaekratoke N; Chamni S; Azam SS; Choowongkomon K; Rungrotmongkol T
    Molecules; 2023 Jan; 28(2):. PubMed ID: 36677654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK/STAT/SOCS-signaling pathway and colon and rectal cancer.
    Slattery ML; Lundgreen A; Kadlubar SA; Bondurant KL; Wolff RK
    Mol Carcinog; 2013 Feb; 52(2):155-66. PubMed ID: 22121102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the JAK/STAT Pathway: A Combined Ligand- and Target-Based Approach.
    Galvez-Llompart M; Ocello R; Rullo L; Stamatakos S; Alessandrini I; Zanni R; Tuñón I; Cavalli A; Candeletti S; Masetti M; Romualdi P; Recanatini M
    J Chem Inf Model; 2021 Jun; 61(6):3091-3108. PubMed ID: 33998810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms.
    Gurska LM; Okabe R; Schurer A; Tong MM; Soto M; Choi D; Ames K; Glushakow-Smith S; Montoya A; Tein E; Miles LA; Cheng H; Hankey-Giblin P; Levine RL; Goel S; Halmos B; Gritsman K
    Clin Cancer Res; 2023 Mar; 29(5):943-956. PubMed ID: 36537918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells.
    Cook AM; Li L; Ho Y; Lin A; Li L; Stein A; Forman S; Perrotti D; Jove R; Bhatia R
    Blood; 2014 May; 123(18):2826-37. PubMed ID: 24668492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selectivity and Ranking of Tight-Binding JAK-STAT Inhibitors Using Markovian Milestoning with Voronoi Tessellations.
    Ojha AA; Srivastava A; Votapka LW; Amaro RE
    J Chem Inf Model; 2023 Apr; 63(8):2469-2482. PubMed ID: 37023323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.
    Bhagwat N; Levine RL; Koppikar P
    Int J Hematol; 2013 Jun; 97(6):695-702. PubMed ID: 23670175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds.
    Migita K; Izumi Y; Torigoshi T; Satomura K; Izumi M; Nishino Y; Jiuchi Y; Nakamura M; Kozuru H; Nonaka F; Eguchi K; Kawakami A; Motokawa S
    Clin Exp Immunol; 2013 Dec; 174(3):356-63. PubMed ID: 23968543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of JAK/STAT signaling pathway and its inhibitors in diseases.
    Xin P; Xu X; Deng C; Liu S; Wang Y; Zhou X; Ma H; Wei D; Sun S
    Int Immunopharmacol; 2020 Mar; 80():106210. PubMed ID: 31972425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.
    Kleppe M; Kwak M; Koppikar P; Riester M; Keller M; Bastian L; Hricik T; Bhagwat N; McKenney AS; Papalexi E; Abdel-Wahab O; Rampal R; Marubayashi S; Chen JJ; Romanet V; Fridman JS; Bromberg J; Teruya-Feldstein J; Murakami M; Radimerski T; Michor F; Fan R; Levine RL
    Cancer Discov; 2015 Mar; 5(3):316-31. PubMed ID: 25572172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway.
    Zheng Y; Qin H; Frank SJ; Deng L; Litchfield DW; Tefferi A; Pardanani A; Lin FT; Li J; Sha B; Benveniste EN
    Blood; 2011 Jul; 118(1):156-66. PubMed ID: 21527517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mining for JAK-STAT mutations in cancer.
    Constantinescu SN; Girardot M; Pecquet C
    Trends Biochem Sci; 2008 Mar; 33(3):122-31. PubMed ID: 18291658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The T-cell leukemia-associated ribosomal RPL10 R98S mutation enhances JAK-STAT signaling.
    Girardi T; Vereecke S; Sulima SO; Khan Y; Fancello L; Briggs JW; Schwab C; de Beeck JO; Verbeeck J; Royaert J; Geerdens E; Vicente C; Bornschein S; Harrison CJ; Meijerink JP; Cools J; Dinman JD; Kampen KR; De Keersmaecker K
    Leukemia; 2018 Mar; 32(3):809-819. PubMed ID: 28744013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual-target Janus kinase (JAK) inhibitors: Comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases.
    Shen P; Wang Y; Jia X; Xu P; Qin L; Feng X; Li Z; Qiu Z
    Eur J Med Chem; 2022 Sep; 239():114551. PubMed ID: 35749986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Jak/STAT pathway is involved in synaptic plasticity.
    Nicolas CS; Peineau S; Amici M; Csaba Z; Fafouri A; Javalet C; Collett VJ; Hildebrandt L; Seaton G; Choi SL; Sim SE; Bradley C; Lee K; Zhuo M; Kaang BK; Gressens P; Dournaud P; Fitzjohn SM; Bortolotto ZA; Cho K; Collingridge GL
    Neuron; 2012 Jan; 73(2):374-90. PubMed ID: 22284190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of JAK/STAT Molecular Pathway in Vascular Remodeling Associated with Pulmonary Hypertension.
    Roger I; Milara J; Montero P; Cortijo J
    Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34067108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK-STAT and JAK-PI3K-mTORC1 pathways regulate telomerase transcriptionally and posttranslationally in ATL cells.
    Yamada O; Ozaki K; Akiyama M; Kawauchi K
    Mol Cancer Ther; 2012 May; 11(5):1112-21. PubMed ID: 22402124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of heat stress on prolactin-mediated ovarian JAK-STAT signaling in postpubertal gilts.
    Roach CM; Bidne KL; Romoser MR; Ross JW; Baumgard LH; Keating AF
    J Anim Sci; 2022 Jul; 100(7):. PubMed ID: 35772766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK2 inhibitors in the treatment of myeloproliferative neoplasms.
    Tibes R; Bogenberger JM; Geyer HL; Mesa RA
    Expert Opin Investig Drugs; 2012 Dec; 21(12):1755-74. PubMed ID: 22991927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.